Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 14 06 2018
accepted: 27 12 2018
pubmed: 11 1 2019
medline: 8 10 2019
entrez: 11 1 2019
Statut: ppublish

Résumé

This study aimed to investigate the prevalence of sleeping problems in prostate cancer survivors and to explore the role of predisposing, precipitating and perpetuating factors in this process. Using a cross-sectional design, 3348 prostate cancer survivors between 2 and 18 years post diagnosis reported experiences of insomnia using the QLQC30, along with their sociodemographic characteristics, health status and treatment(s) received. The EQ5D-5L and QLQPR25 assessed survivors' overall and prostate cancer-specific health-related quality of life. A hierarchical multiple regression analysis was constructed with three blocks: (1) predisposing (e.g. demographics at diagnosis), (2) precipitating (e.g. disease extent, treatment) and (3) perpetuating factors (e.g. side effects). Nineteen percent of survivors reported significant problems sleeping. The final model accounted for 31% of the variance in insomnia scores (p < .001). In order of magnitude, associates of sleep disturbance were urinary symptoms (β = 0.22; p < .001), experiencing symptoms of depression/anxiety (β = 0.18; p < .001), hormone treatment-related symptoms (β = 0.12; p = .001), pain (β = 0.10; p < .001) and bowel symptoms (β = 0.06; p = .005). Having a lower education and more comorbidities at diagnosis also predicted sleep problems. Results suggest that it is the ongoing adverse effects of prostate cancer and its treatment (e.g. urinary symptoms) that put survivors most at risk of sleep problems. Strong associations with symptoms of depression/anxiety were also observed. Findings highlight the need for health care practitioners to treat and manage adverse effects of prostate cancer treatment in order to mitigate sleep disturbance in survivors.

Identifiants

pubmed: 30627919
doi: 10.1007/s00520-018-4633-z
pii: 10.1007/s00520-018-4633-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3365-3373

Subventions

Organisme : Prostate Cancer UK
ID : NI09-03
Pays : United Kingdom
Organisme : National Cancer Control Programme RoI
ID : NA
Organisme : Public Health Agency NI
ID : NA
Organisme : Prostate Cancer UK
ID : NI-PG13-001
Pays : United Kingdom
Organisme : Prostate Cancer UK
ID : NI09-03 & NI-PG13-001
Pays : United Kingdom
Organisme : Health Research Board
ID : HRA_HSR/2010/17
Pays : Ireland

Références

Drummond F, Kinnear H, O’Leary E, Donnelly GA, Sharp L (2015) Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv 9(2):361–372. https://doi.org/10.1007/s11764-014-0419-6
doi: 10.1007/s11764-014-0419-6 pubmed: 25563819
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250–1261. https://doi.org/10.1056/NEJMoa074311
doi: 10.1056/NEJMoa074311
Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH (1995) Quality-of-life outcomes in men treated for localized prostate cancer. Jama 273(2):129–135
doi: 10.1001/jama.1995.03520260051032 pubmed: 7799493
Drummond FJ (2016) Are we sleeping on the job? Insomnia among men with prostate cancer. Adv Mod Oncol Res 2:74
doi: 10.18282/amor.v2.i2.94
Roscoe JA, Kaufman ME, Matteson-Rusby SE, Palesh OG, Ryan JL, Kohli S, Perlis ML, Morrow GR (2007) Cancer-related fatigue and sleep disorders. Oncologist 12(Suppl 1):35–42. https://doi.org/10.1634/theoncologist.12-S1-35
doi: 10.1634/theoncologist.12-S1-35 pubmed: 17573454
Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM (2011) Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol 29(26):3580–3586. https://doi.org/10.1200/jco.2010.33.2247
doi: 10.1200/JCO.2010.33.2247 pubmed: 21825267
Zhou ES, Partridge AH, Syrjala KL, Michaud AL, Recklitis CJ (2017) Evaluation and treatment of insomnia in adult cancer survivorship programs. J Cancer Surviv 11(1):74–79. https://doi.org/10.1007/s11764-016-0564-1
doi: 10.1007/s11764-016-0564-1 pubmed: 27495283
Dirksen SR, Epstein DR, Hoyt MA (2009) Insomnia, depression, and distress among outpatients with prostate cancer. Appl Nurs Res 22(3):154–158. https://doi.org/10.1016/j.apnr.2007.09.001
doi: 10.1016/j.apnr.2007.09.001 pubmed: 19616162
Savard J, Simard S, Hervouet S, Ivers H, Lacombe L, Fradet Y (2005) Insomnia in men treated with radical prostatectomy for prostate cancer. Psychooncology 14(2):147–156. https://doi.org/10.1002/pon.830
doi: 10.1002/pon.830 pubmed: 15386779
Mystakidou K, Parpa E, Tsilika E, Pathiaki M, Patiraki E, Galanos A, Vlahos L (2007) Sleep quality in advanced cancer patients. J Psychosom Res 62(5):527–533. https://doi.org/10.1016/j.jpsychores.2006.11.008
doi: 10.1016/j.jpsychores.2006.11.008 pubmed: 17467407
Roth T, Franklin M, Bramley TJ (2007) The state of insomnia and emerging trends. Am J Manag Care 13(5 Suppl):S117–S120
pubmed: 18041871
Savard J, Ivers H, Savard MH, Morin CM (2015) Cancer treatments and their side effects are associated with aggravation of insomnia: results of a longitudinal study. Cancer 121(10):1703–1711. https://doi.org/10.1002/cncr.29244
doi: 10.1002/cncr.29244 pubmed: 25677509
Savard J, Hervouet S, Ivers H (2013) Prostate cancer treatments and their side effects are associated with increased insomnia. Psychooncology 22(6):1381–1388. https://doi.org/10.1002/pon.3150
doi: 10.1002/pon.3150 pubmed: 22888075
Miaskowski C, Paul SM, Cooper BA, Lee K, Dodd M, West C, Aouizerat BE, Dunn L, Swift PS, Wara W (2011) Predictors of the trajectories of self-reported sleep disturbance in men with prostate cancer during and following radiation therapy. Sleep 34(2):171–179
doi: 10.1093/sleep/34.2.171 pubmed: 21286498 pmcid: 3022937
Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Cartoni C, Pizzuto M, Caruselli A, Parsi R, Cortegiani A, Masedu F, Valenti M, Ficorella C, Porzio G (2015) Sleep disturbances in patients with advanced cancer in different palliative care settings. J Pain Symptom Manag 50(6):786–792. https://doi.org/10.1016/j.jpainsymman.2015.06.018
doi: 10.1016/j.jpainsymman.2015.06.018
Singareddy R, Vgontzas AN, Fernandez-Mendoza J, Liao D, Calhoun S, Shaffer ML, Bixler EO (2012) Risk factors for incident chronic insomnia: a general population prospective study. Sleep Med 13(4):346–353. https://doi.org/10.1016/j.sleep.2011.10.033
doi: 10.1016/j.sleep.2011.10.033 pubmed: 22425576 pmcid: 3319648
Spielman AJ, Caruso LS, Glovinsky PB (1987) A behavioral perspective on insomnia treatment. Psychiatr Clin 10(4):541–553
Fiorentino L, Rissling M, Liu L, Ancoli-Israel S (2011) The symptom cluster of sleep, fatigue and depressive symptoms in breast cancer patients: severity of the problem and treatment options. Drug Discov Today Dis Model 8(4):167–173
doi: 10.1016/j.ddmod.2011.05.001
Savard J, Morin CM (2001) Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 19(3):895–908
doi: 10.1200/JCO.2001.19.3.895 pubmed: 11157043
Savard J, Villa J, Ivers H, Simard S, Morin CM (2009) Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. J Clin Oncol 27(31):5233–5239
doi: 10.1200/JCO.2008.21.6333 pubmed: 19738124
Garland SN, Barg FK, Cakouros B, Gehrman P, DuHamel KN, Mao JJ (2018) A qualitative examination of the factors related to the development and maintenance of insomnia in cancer survivors. Palliat Support Care:1–6. https://doi.org/10.1017/S1478951518000135
Sivertsen B, Salo P, Mykletun A, Hysing M, Pallesen S, Krokstad S, Nordhus IH, Overland S (2012) The bidirectional association between depression and insomnia: the HUNT study. Psychosom Med 74(7):758–765. https://doi.org/10.1097/PSY.0b013e3182648619
doi: 10.1097/PSY.0b013e3182648619 pubmed: 22879427
LeBlanc M, Merette C, Savard J, Ivers H, Baillargeon L, Morin CM (2009) Incidence and risk factors of insomnia in a population-based sample. Sleep 32(8):1027–1037
doi: 10.1093/sleep/32.8.1027 pubmed: 19725254 pmcid: 2717193
Maguire R, Hanly P, Drummond FJ, Gavin A, Sharp L (2018) Expecting the worst? The relationship between retrospective and prospective appraisals of illness on quality of life in prostate cancer survivors. Psychooncology 27(4):1237–1243. https://doi.org/10.1002/pon.4660
doi: 10.1002/pon.4660 pubmed: 29430755
Drummond F, Kinnear H, Donnelly C, O’Leary E, O’Brien K, Burns R, Gavin A, Sharp L (2015) Establishing a population-based patient-reported outcomes study (PROMs) using national cancer registries across two jurisdictions: the prostate cancer treatment, your experience (PiCTure) study. BMJ Open 5(4):e006851. https://doi.org/10.1136/bmjopen-2014-006851
doi: 10.1136/bmjopen-2014-006851 pubmed: 25888474 pmcid: 4401862
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
doi: 10.1093/jnci/85.5.365 pubmed: 8433390 pmcid: 8433390
Steentjes L, Siesling S, Drummond FJ, van Manen JG, Sharp L, Gavin A (2016) Factors associated with current and severe physical side-effects after prostate cancer treatment: what men report. Eur J Cancer Care (Engl) 27. https://doi.org/10.1111/ecc.12589
van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, D’Haese S, Aaronson NK (2008) An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 44(16):2418–2424. https://doi.org/10.1016/j.ejca.2008.07.030
doi: 10.1016/j.ejca.2008.07.030 pubmed: 18774706
O’Leary E, Drummond FJ, Gavin A, Kinnear H, Sharp L (2015) Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg. Qual Life Res 24(9):2219–2230. https://doi.org/10.1007/s11136-015-0958-y
doi: 10.1007/s11136-015-0958-y pubmed: 25791618
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727–1736. https://doi.org/10.1007/s11136-011-9903-x
doi: 10.1007/s11136-011-9903-x pubmed: 21479777 pmcid: 3220807
Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S (2007) Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 45:259–263
doi: 10.1097/01.mlr.0000254515.63841.81 pubmed: 17304084
Juul T, Petersen MA, Holzner B, Laurberg S, Christensen P, Grønvold M (2014) Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity. Qual Life Res 23(8):2183–2193
doi: 10.1007/s11136-014-0675-y pubmed: 24676897
Waldmann A, Schubert D, Katalinic A (2013) Normative data of the EORTC QLQ-C30 for the German population: a population-based survey. PLoS One 8(9):e74149
doi: 10.1371/journal.pone.0074149 pubmed: 24058523 pmcid: 3769241
Li X, Wong W, Lamoureux EL, Wong TY (2012) Are linear regression techniques appropriate for analysis when the dependent (outcome) variable is not normally distributed? Invest Ophthalmol Vis Sci 53(6):3082–3083
doi: 10.1167/iovs.12-9967 pubmed: 22618757
Scott NW, Fayers P, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Gundy C, Koller M, Petersen MA, Sprangers MA (2008) EORTC QLQ-C30 reference values manual
Drummond FJ, Gavin AT, Sharp L (2017) Supportive medications and interventions received by prostate cancer survivors: results from the PiCTure study. J Community Support Oncol 15(6):e309–e313
doi: 10.12788/jcso.0384
Knutson K (2015) Sleep and pain: summary of the 2015 sleep in America poll. Sleep Health 1(2):85. https://doi.org/10.1016/j.sleh.2015.03.006
doi: 10.1016/j.sleh.2015.03.006 pubmed: 29073381
Hoyt MA, Bower JE, Irwin MR, Weierich MR, Stanton AL (2016) Sleep quality and depressive symptoms after prostate cancer: the mechanistic role of cortisol. Behav Neurosci 130(3):351–356
doi: 10.1037/bne0000107 pubmed: 26820589 pmcid: 4877249
Sharp L, O’Leary E, Kinnear H, Gavin A, Drummond FJ (2016) Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psychooncology 25(3):282–291. https://doi.org/10.1002/pon.3909
doi: 10.1002/pon.3909 pubmed: 26249170
Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, Lewith G (2014) Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 4(3):e003901. https://doi.org/10.1136/bmjopen-2013-003901
doi: 10.1136/bmjopen-2013-003901 pubmed: 24625637 pmcid: 3963074
Maguire R, Hanly P, Drummond F, Gavin A, Sharp L (2017) Regret and fear in prostate cancer: the relationship between treatment appraisals and fear of recurrence in prostate cancer survivors. Psycho-Oncology 26(11):1825–1831. https://doi.org/10.1002/pon.4384
doi: 10.1002/pon.4384 pubmed: 28124398
Cordova MJ, Riba MB, Spiegel D (2017) Post-traumatic stress disorder and cancer. Lancet Psychiatry 4(4):330–338. https://doi.org/10.1016/s2215-0366(17)30014-7
doi: 10.1016/S2215-0366(17)30014-7 pubmed: 28109647 pmcid: 5676567
Pigeon WR, Campbell CE, Possemato K, Ouimette P (2013) Longitudinal relationships of insomnia, nightmares, and PTSD severity in recent combat veterans. J Psychosom Res 75(6):546–550. https://doi.org/10.1016/j.jpsychores.2013.09.004
doi: 10.1016/j.jpsychores.2013.09.004 pubmed: 24290044
Johnson JA, Rash JA, Campbell TS, Savard J, Gehrman PR, Perlis M, Carlson LE, Garland SN (2016) A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. Sleep Med Rev 27:20–28. https://doi.org/10.1016/j.smrv.2015.07.001
doi: 10.1016/j.smrv.2015.07.001 pubmed: 26434673

Auteurs

Rebecca Maguire (R)

Department of Psychology, Maynooth University, Maynooth, Co. Kildare, Ireland. rebecca.maguire@mu.ie.

Frances J Drummond (FJ)

Cancer Research @ UCC, University College Cork, Cork, Ireland.

Paul Hanly (P)

National College of Ireland, Mayor Street, Dublin 1, Ireland.

Anna Gavin (A)

Queens University Belfast, Belfast, UK.

Linda Sharp (L)

Newcastle University, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH